234 related articles for article (PubMed ID: 36356286)
1. Circulating Tumor DNA as a Marker of Minimal Residual Disease After Radical Resection of Colorectal Liver Metastases.
Marmorino F; Prisciandaro M; Giordano M; Ortolan E; Crucitta S; Manca P; Antoniotti C; Valenti MM; Danesi R; Conca V; Mazzoli G; Boccaccino A; Carullo M; Martinetti A; Sottotetti E; Masi G; Sposito C; Zaffaroni N; Milione M; Fontanini G; Del Re M; Pietrantonio F; Cremolini C
JCO Precis Oncol; 2022 Nov; 6():e2200244. PubMed ID: 36356286
[TBL] [Abstract][Full Text] [Related]
2. Targeted next-generation sequencing of circulating-tumor DNA for tracking minimal residual disease in localized colon cancer.
Tarazona N; Gimeno-Valiente F; Gambardella V; Zuñiga S; Rentero-Garrido P; Huerta M; Roselló S; Martinez-Ciarpaglini C; Carbonell-Asins JA; Carrasco F; Ferrer-Martínez A; Bruixola G; Fleitas T; Martín J; Tébar-Martínez R; Moro D; Castillo J; Espí A; Roda D; Cervantes A
Ann Oncol; 2019 Nov; 30(11):1804-1812. PubMed ID: 31562764
[TBL] [Abstract][Full Text] [Related]
3. Circulating Tumor DNA as a Minimal Residual Disease Assessment and Recurrence Risk in Patients Undergoing Curative-Intent Resection with or without Adjuvant Chemotherapy in Colorectal Cancer: A Systematic Review and Meta-Analysis.
Chidharla A; Rapoport E; Agarwal K; Madala S; Linares B; Sun W; Chakrabarti S; Kasi A
Int J Mol Sci; 2023 Jun; 24(12):. PubMed ID: 37373376
[TBL] [Abstract][Full Text] [Related]
4. Circulating tumor DNA dynamics and recurrence risk in patients undergoing curative intent resection of colorectal cancer liver metastases: A prospective cohort study.
Tie J; Wang Y; Cohen J; Li L; Hong W; Christie M; Wong HL; Kosmider S; Wong R; Thomson B; Choi J; Fox A; Field K; Burge M; Shannon J; Kotasek D; Tebbutt NC; Karapetis C; Underhill C; Haydon A; Schaeffer J; Ptak J; Tomasetti C; Papadopoulos N; Kinzler KW; Vogelstein B; Gibbs P
PLoS Med; 2021 May; 18(5):e1003620. PubMed ID: 33939694
[TBL] [Abstract][Full Text] [Related]
5. Circulating tumor DNA for prognosis assessment and postoperative management after curative-intent resection of colorectal liver metastases.
Reinert T; Petersen LMS; Henriksen TV; Larsen MØ; Rasmussen MH; Johansen AFB; Øgaard N; Knudsen M; Nordentoft I; Vang S; Krag SRP; Knudsen AR; Mortensen FV; Andersen CL
Int J Cancer; 2022 May; 150(9):1537-1548. PubMed ID: 34994972
[TBL] [Abstract][Full Text] [Related]
6. Circulating Tumor DNA as a Prognostic Factor in Patients With Resectable Hepatic Metastases of Uveal Melanoma.
Mariani P; Bidard FC; Rampanou A; Houy A; Servois V; Ramtohul T; Pierron G; Chevrier M; Renouf B; Lantz O; Gardrat S; Vincent-Salomon A; Roman-Roman S; Rodrigues M; Piperno-Neumann S; Cassoux N; Stern MH; Renault S
Ann Surg; 2023 Oct; 278(4):e827-e834. PubMed ID: 36847256
[TBL] [Abstract][Full Text] [Related]
7. Detection of Molecular Residual Disease Using Personalized Circulating Tumor DNA Assay in Patients With Colorectal Cancer Undergoing Resection of Metastases.
Loupakis F; Sharma S; Derouazi M; Murgioni S; Biason P; Rizzato MD; Rasola C; Renner D; Shchegrova S; Koyen Malashevich A; Malhotra M; Sethi H; Zimmermann BG; Aleshin A; Moshkevich S; Billings PR; Sedgwick JD; Schirripa M; Munari G; Cillo U; Pilati P; Dei Tos AP; Zagonel V; Lonardi S; Fassan M
JCO Precis Oncol; 2021 Jul; 5():. PubMed ID: 34327297
[TBL] [Abstract][Full Text] [Related]
8. Dynamic monitoring of circulating tumor DNA to predict prognosis and efficacy of adjuvant chemotherapy after resection of colorectal liver metastases.
Wang DS; Yang H; Liu XY; Chen ZG; Wang Y; Fong WP; Hu MT; Zheng YC; Zheng Y; Li BK; Yuan YF; Chen G; Pan ZZ; Song L; Li YH; Xu RH
Theranostics; 2021; 11(14):7018-7028. PubMed ID: 34093868
[No Abstract] [Full Text] [Related]
9. Prognostic impact of postoperative circulating tumor DNA as a molecular minimal residual disease marker in patients with pancreatic cancer undergoing surgical resection.
Hata T; Mizuma M; Motoi F; Ohtsuka H; Nakagawa K; Morikawa T; Unno M
J Hepatobiliary Pancreat Sci; 2023 Jun; 30(6):815-824. PubMed ID: 36408698
[TBL] [Abstract][Full Text] [Related]
10. Comprehensive Genomic Profiling (CGP)-Informed Personalized Molecular Residual Disease (MRD) Detection: An Exploratory Analysis from the PREDATOR Study of Metastatic Colorectal Cancer (mCRC) Patients Undergoing Surgical Resection.
Lonardi S; Nimeiri H; Xu C; Zollinger DR; Madison RW; Fine AD; Gjoerup O; Rasola C; Angerilli V; Sharma S; Wu HT; Palsuledesai CC; Malhotra M; Aleshin A; Loupakis F; Renkonen E; Hegde P; Fassan M
Int J Mol Sci; 2022 Sep; 23(19):. PubMed ID: 36232827
[TBL] [Abstract][Full Text] [Related]
11. Personalized circulating tumor DNA monitoring improves recurrence surveillance and management after curative resection of colorectal liver metastases: a prospective cohort study.
Li Y; Xu J; Hu X; Chen Y; Liu F; Chen Y; Ma X; Dong Q; Sun L; Mo S; Zhang L; He X; Tong S; Wu H; Li W; Cai S; Zhu S; Pan Q; Peng J
Int J Surg; 2024 May; 110(5):2776-2787. PubMed ID: 38445460
[TBL] [Abstract][Full Text] [Related]
12. Utility of Circulating Tumor DNA Assessment in Characterizing Recurrence Sites after Optimal Resection for Metastatic Colorectal Cancer.
Bansal VV; Belmont E; Godley F; Dhiman A; Witmer HD; Li S; Liao A; Eng OS; Turaga KK; Shergill A
J Am Coll Surg; 2024 Jun; 238(6):1013-1020. PubMed ID: 38299640
[TBL] [Abstract][Full Text] [Related]
13. Significance of postoperative follow-up of patients with metastatic colorectal cancer using circulating tumor DNA.
Benešová L; Hálková T; Ptáčková R; Semyakina A; Menclová K; Pudil J; Ryska M; Levý M; Šimša J; Pazdírek F; Hoch J; Blaha M; Minárik M
World J Gastroenterol; 2019 Dec; 25(48):6939-6948. PubMed ID: 31908397
[TBL] [Abstract][Full Text] [Related]
14. Circulating Tumor DNA Analyses as Markers of Recurrence Risk and Benefit of Adjuvant Therapy for Stage III Colon Cancer.
Tie J; Cohen JD; Wang Y; Christie M; Simons K; Lee M; Wong R; Kosmider S; Ananda S; McKendrick J; Lee B; Cho JH; Faragher I; Jones IT; Ptak J; Schaeffer MJ; Silliman N; Dobbyn L; Li L; Tomasetti C; Papadopoulos N; Kinzler KW; Vogelstein B; Gibbs P
JAMA Oncol; 2019 Dec; 5(12):1710-1717. PubMed ID: 31621801
[TBL] [Abstract][Full Text] [Related]
15. Circulating tumor DNA is a prognostic marker of tumor recurrence in stage II and III colorectal cancer: multicentric, prospective cohort study (ALGECOLS).
Benhaim L; Bouché O; Normand C; Didelot A; Mulot C; Le Corre D; Garrigou S; Djadi-Prat J; Wang-Renault SF; Perez-Toralla K; Pekin D; Poulet G; Landi B; Taieb J; Selvy M; Emile JF; Lecomte T; Blons H; Chatellier G; Link DR; Taly V; Laurent-Puig P
Eur J Cancer; 2021 Dec; 159():24-33. PubMed ID: 34731746
[TBL] [Abstract][Full Text] [Related]
16. Initial Report: Personalized Circulating Tumor DNA and Survival in Patients with Resectable Pancreatic Cancer.
Eckhoff AM; Kanu E; Fletcher A; Bao M; Aushev VN; Spickard E; Nussbaum DP; Allen PJ
Ann Surg Oncol; 2024 Mar; 31(3):1444-1446. PubMed ID: 38170407
[TBL] [Abstract][Full Text] [Related]
17. Tumour-agnostic circulating tumour DNA analysis for improved recurrence surveillance after resection of colorectal liver metastases: A prospective cohort study.
Øgaard N; Reinert T; Henriksen TV; Frydendahl A; Aagaard E; Ørntoft MW; Larsen MØ; Knudsen AR; Mortensen FV; Andersen CL
Eur J Cancer; 2022 Mar; 163():163-176. PubMed ID: 35074652
[TBL] [Abstract][Full Text] [Related]
18. Circulating tumor DNA as a marker of minimal residual disease following local treatment of metastases from colorectal cancer.
Boysen AK; Pallisgaard N; Andersen CSA; Spindler KG
Acta Oncol; 2020 Dec; 59(12):1424-1429. PubMed ID: 32790489
[TBL] [Abstract][Full Text] [Related]
19. ctDNA-based minimal residual disease detection in lung cancer patients treated with curative intended chemoradiotherapy using a clinically transferable approach.
Nielsen LR; Stensgaard S; Meldgaard P; Sorensen BS
Cancer Treat Res Commun; 2024; 39():100802. PubMed ID: 38428066
[TBL] [Abstract][Full Text] [Related]
20. Early assessment of circulating tumor DNA after curative-intent resection predicts tumor recurrence in early-stage and locally advanced non-small-cell lung cancer.
Waldeck S; Mitschke J; Wiesemann S; Rassner M; Andrieux G; Deuter M; Mutter J; Lüchtenborg AM; Kottmann D; Titze L; Zeisel C; Jolic M; Philipp U; Lassmann S; Bronsert P; Greil C; Rawluk J; Becker H; Isbell L; Müller A; Doostkam S; Passlick B; Börries M; Duyster J; Wehrle J; Scherer F; von Bubnoff N
Mol Oncol; 2022 Jan; 16(2):527-537. PubMed ID: 34653314
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
